Wall Street Zen Upgrades OraSure Technologies (NASDAQ:OSUR) to Hold

Key Points

• Wall Street Zen upgraded OraSure Technologies from “sell” to “hold,” while Weiss Ratings maintained a sell-oriented rating. Analysts overall rate the stock “Reduce,” with an average price target of $3.00.
• OSUR opened at $4.05, near its 52-week high of $4.58, with a market capitalization of approximately $278.8 million. The company has a negative price-to-earnings ratio of -5.87.
• Institutional investors own 93.5% of OraSure’s shares, including a new $27.9 million position from BlackRock. Director Steven Kyle Boyd also increased his holdings by 28.26% through a 25,000-share purchase.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

Separately, Weiss Ratings upgraded OraSure Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, June 4th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average price target of $3.00.

OraSure Technologies Stock Performance

Shares of OSUR opened at $4.05 on Monday. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.58. The stock has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.43. The stock has a market cap of $278.84 million, a PE ratio of -5.87 and a beta of 1.00.

Insiders Place Their Bets

In other news, Director Steven Kyle Boyd acquired 25,000 shares of the company's stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $2.99 per share, with a total value of $74,750.00. Following the completion of the acquisition, the director owned 113,462 shares in the company, valued at approximately $339,251.38. This represents a 28.26% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On OraSure Technologies

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in OraSure Technologies in the 2nd quarter valued at $27,905,000. Deutsche Bank AG bought a new stake in shares of OraSure Technologies during the second quarter worth $527,000. OneDigital Investment Advisors LLC bought a new stake in shares of OraSure Technologies during the second quarter worth $91,000. Bank of New York Mellon Corp acquired a new stake in shares of OraSure Technologies in the second quarter valued at $926,000. Finally, Marquette Asset Management LLC acquired a new stake in shares of OraSure Technologies in the second quarter valued at $601,000. 93.50% of the stock is currently owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source